FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313645055> ?p ?o ?g. }

• W4313645055 abstract "Abstract Background Despite new and better treatments for juvenile dermatomyositis (JDM), not all patients with moderate severity disease respond adequately to first-line therapy. Those with refractory disease remain at higher risk for disease and glucocorticoid-related complications. Biologic disease-modifying antirheumatic drugs (DMARDs) have become part of the arsenal of treatments for JDM. However, prospective comparative studies of commonly used biologics are lacking. Methods The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM biologics workgroup met in 2019 and produced a survey assessing current treatment escalation practices for JDM, including preferences regarding use of biologic treatments. The cases and questions were developed using a consensus framework, requiring 80% agreement for consensus. The survey was completed online in 2020 by CARRA members interested in JDM. Survey results were analyzed among all respondents and according to years of experience. Chi-square or Fisher’s exact test was used to compare the distribution of responses to each survey question. Results One hundred twenty-one CARRA members responded to the survey (denominators vary for each question). Of the respondents, 88% were pediatric rheumatologists, 85% practiced in the United States, and 43% had over 10 years of experience. For a patient with moderately severe JDM refractory to methotrexate, glucocorticoids, and IVIG, approximately 80% of respondents indicated that they would initiate a biologic after failing 1–2 non-biologic DMARDs. Trials of methotrexate and mycophenolate were considered necessary by 96% and 60% of respondents, respectively, before initiating a biologic. By weighed average, rituximab was the preferred biologic over abatacept, tocilizumab, and infliximab. Over 50% of respondents would start a biologic by 4 months from diagnosis for patients with refractory moderately severe JDM. There were no notable differences in treatment practices between respondents by years of experience. Conclusion Most respondents favored starting a biologic earlier in disease course after trialing up to two conventional DMARDs, specifically including methotrexate. There was a clear preference for rituximab. However, there remains a dearth of prospective data comparing biologics in refractory JDM. These findings underscore the need for biologic consensus treatment plans (CTPs) for refractory JDM, which will ultimately facilitate comparative effectiveness studies and inform treatment practices." @default.
• W4313645055 created "2023-01-07" @default.
• W4313645055 creator A5002183437 @default.
• W4313645055 creator A5009088784 @default.
• W4313645055 creator A5023961894 @default.
• W4313645055 creator A5029067941 @default.
• W4313645055 creator A5032808585 @default.
• W4313645055 creator A5057785052 @default.
• W4313645055 creator A5059169622 @default.
• W4313645055 creator A5079551133 @default.
• W4313645055 creator A5083460869 @default.
• W4313645055 creator A5083490131 @default.
• W4313645055 creator A5086244702 @default.
• W4313645055 creator A5087468483 @default.
• W4313645055 creator A5087789080 @default.
• W4313645055 creator A5091884614 @default.
• W4313645055 date "2023-01-06" @default.
• W4313645055 modified "2023-09-25" @default.
• W4313645055 title "Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance" @default.
• W4313645055 cites W1986992328 @default.
• W4313645055 cites W2001653269 @default.
• W4313645055 cites W2044076811 @default.
• W4313645055 cites W2064304125 @default.
• W4313645055 cites W2076417190 @default.
• W4313645055 cites W2086052247 @default.
• W4313645055 cites W2517958812 @default.
• W4313645055 cites W2626024150 @default.
• W4313645055 cites W2757414514 @default.
• W4313645055 cites W2795151550 @default.
• W4313645055 cites W2809423079 @default.
• W4313645055 cites W2810460332 @default.
• W4313645055 cites W2969640262 @default.
• W4313645055 cites W2979984526 @default.
• W4313645055 cites W3028499663 @default.
• W4313645055 cites W3080901368 @default.
• W4313645055 cites W3123318227 @default.
• W4313645055 cites W3182275447 @default.
• W4313645055 cites W3196974750 @default.
• W4313645055 cites W3203976771 @default.
• W4313645055 cites W4200635597 @default.
• W4313645055 cites W4221009615 @default.
• W4313645055 cites W4285719527 @default.
• W4313645055 doi "https://doi.org/10.1186/s12969-022-00785-5" @default.
• W4313645055 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36609397" @default.
• W4313645055 hasPublicationYear "2023" @default.
• W4313645055 type Work @default.
• W4313645055 citedByCount "0" @default.
• W4313645055 crossrefType "journal-article" @default.
• W4313645055 hasAuthorship W4313645055A5002183437 @default.
• W4313645055 hasAuthorship W4313645055A5009088784 @default.
• W4313645055 hasAuthorship W4313645055A5023961894 @default.
• W4313645055 hasAuthorship W4313645055A5029067941 @default.
• W4313645055 hasAuthorship W4313645055A5032808585 @default.
• W4313645055 hasAuthorship W4313645055A5057785052 @default.
• W4313645055 hasAuthorship W4313645055A5059169622 @default.
• W4313645055 hasAuthorship W4313645055A5079551133 @default.
• W4313645055 hasAuthorship W4313645055A5083460869 @default.
• W4313645055 hasAuthorship W4313645055A5083490131 @default.
• W4313645055 hasAuthorship W4313645055A5086244702 @default.
• W4313645055 hasAuthorship W4313645055A5087468483 @default.
• W4313645055 hasAuthorship W4313645055A5087789080 @default.
• W4313645055 hasAuthorship W4313645055A5091884614 @default.
• W4313645055 hasBestOaLocation W43136450551 @default.
• W4313645055 hasConcept C126322002 @default.
• W4313645055 hasConcept C1862650 @default.
• W4313645055 hasConcept C198451711 @default.
• W4313645055 hasConcept C2777178219 @default.
• W4313645055 hasConcept C2778552304 @default.
• W4313645055 hasConcept C2779134260 @default.
• W4313645055 hasConcept C2779338263 @default.
• W4313645055 hasConcept C2779605438 @default.
• W4313645055 hasConcept C2780653079 @default.
• W4313645055 hasConcept C2781059491 @default.
• W4313645055 hasConcept C512399662 @default.
• W4313645055 hasConcept C71924100 @default.
• W4313645055 hasConceptScore W4313645055C126322002 @default.
• W4313645055 hasConceptScore W4313645055C1862650 @default.
• W4313645055 hasConceptScore W4313645055C198451711 @default.
• W4313645055 hasConceptScore W4313645055C2777178219 @default.
• W4313645055 hasConceptScore W4313645055C2778552304 @default.
• W4313645055 hasConceptScore W4313645055C2779134260 @default.
• W4313645055 hasConceptScore W4313645055C2779338263 @default.
• W4313645055 hasConceptScore W4313645055C2779605438 @default.
• W4313645055 hasConceptScore W4313645055C2780653079 @default.
• W4313645055 hasConceptScore W4313645055C2781059491 @default.
• W4313645055 hasConceptScore W4313645055C512399662 @default.
• W4313645055 hasConceptScore W4313645055C71924100 @default.
• W4313645055 hasFunder F4320332161 @default.
• W4313645055 hasIssue "1" @default.
• W4313645055 hasLocation W43136450551 @default.
• W4313645055 hasLocation W43136450552 @default.
• W4313645055 hasLocation W43136450553 @default.
• W4313645055 hasOpenAccess W4313645055 @default.
• W4313645055 hasPrimaryLocation W43136450551 @default.
• W4313645055 hasRelatedWork W2100412217 @default.
• W4313645055 hasRelatedWork W2102593826 @default.
• W4313645055 hasRelatedWork W2205711752 @default.
• W4313645055 hasRelatedWork W2303252670 @default.
• W4313645055 hasRelatedWork W2545675757 @default.
• W4313645055 hasRelatedWork W2908523333 @default.

• next